179 related articles for article (PubMed ID: 37385350)
1. Coenzyme Q10 exhibits anti-inflammatory and immune-modulatory thereby decelerating the occurrence of experimental cerebral malaria.
Nyariki JN; Kimani NM; Kibet PS; Kinuthia GK; Isaac AO
Mol Biochem Parasitol; 2023 Sep; 255():111579. PubMed ID: 37385350
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of Coenzyme Q
Nyariki JN; Ochola LA; Jillani NE; Nyamweya NO; Amwayi PE; Yole DS; Azonvide L; Isaac AO
Parasitol Int; 2019 Aug; 71():106-120. PubMed ID: 30981893
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing Schistosoma japonicum infection alters the immune response to Plasmodium berghei infection in C57BL/6 mice.
Wang ML; Cao YM; Luo EJ; Zhang Y; Guo YJ
Malar J; 2013 Sep; 12():322. PubMed ID: 24034228
[TBL] [Abstract][Full Text] [Related]
4. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA.
Palomo J; Fauconnier M; Coquard L; Gilles M; Meme S; Szeremeta F; Fick L; Franetich JF; Jacobs M; Togbe D; Beloeil JC; Mazier D; Ryffel B; Quesniaux VF
Eur J Immunol; 2013 Oct; 43(10):2683-95. PubMed ID: 23780878
[TBL] [Abstract][Full Text] [Related]
5. Doxycycline inhibits experimental cerebral malaria by reducing inflammatory immune reactions and tissue-degrading mediators.
Schmidt KE; Kuepper JM; Schumak B; Alferink J; Hofmann A; Howland SW; Rénia L; Limmer A; Specht S; Hoerauf A
PLoS One; 2018; 13(2):e0192717. PubMed ID: 29438386
[TBL] [Abstract][Full Text] [Related]
6. Protection of Batf3-deficient mice from experimental cerebral malaria correlates with impaired cytotoxic T-cell responses and immune regulation.
Kuehlwein JM; Borsche M; Korir PJ; Risch F; Mueller AK; Hübner MP; Hildner K; Hoerauf A; Dunay IR; Schumak B
Immunology; 2020 Feb; 159(2):193-204. PubMed ID: 31631339
[TBL] [Abstract][Full Text] [Related]
7. Critical role of IL-33 receptor ST2 in experimental cerebral malaria development.
Palomo J; Reverchon F; Piotet J; Besnard AG; Couturier-Maillard A; Maillet I; Tefit M; Erard F; Mazier D; Ryffel B; Quesniaux VF
Eur J Immunol; 2015 May; 45(5):1354-65. PubMed ID: 25682948
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D inhibits the occurrence of experimental cerebral malaria in mice by suppressing the host inflammatory response.
He X; Yan J; Zhu X; Wang Q; Pang W; Qi Z; Wang M; Luo E; Parker DM; Cantorna MT; Cui L; Cao Y
J Immunol; 2014 Aug; 193(3):1314-23. PubMed ID: 24965778
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel CD4
Fernandez-Ruiz D; Lau LS; Ghazanfari N; Jones CM; Ng WY; Davey GM; Berthold D; Holz L; Kato Y; Enders MH; Bayarsaikhan G; Hendriks SH; Lansink LIM; Engel JA; Soon MSF; James KR; Cozijnsen A; Mollard V; Uboldi AD; Tonkin CJ; de Koning-Ward TF; Gilson PR; Kaisho T; Haque A; Crabb BS; Carbone FR; McFadden GI; Heath WR
J Immunol; 2017 Dec; 199(12):4165-4179. PubMed ID: 29084838
[TBL] [Abstract][Full Text] [Related]
10. Neuregulin-1 attenuates experimental cerebral malaria (ECM) pathogenesis by regulating ErbB4/AKT/STAT3 signaling.
Liu M; Solomon W; Cespedes JC; Wilson NO; Ford B; Stiles JK
J Neuroinflammation; 2018 Apr; 15(1):104. PubMed ID: 29636063
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of chloroquine and coenzyme Q
Ouko DB; Amwayi PW; Ochola LA; Wairagu PM; Isaac AO; Nyariki JN
J Parasit Dis; 2022 Jun; 46(2):466-475. PubMed ID: 35692470
[TBL] [Abstract][Full Text] [Related]
12. Neuregulin-1 attenuates mortality associated with experimental cerebral malaria.
Solomon W; Wilson NO; Anderson L; Pitts S; Patrickson J; Liu M; Ford BD; Stiles JK
J Neuroinflammation; 2014 Jan; 11():9. PubMed ID: 24433482
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of artesunate combined with Atractylodes lancea or Prabchompoothaweep remedy extracts as adjunctive therapy for the treatment of cerebral malaria.
Plirat W; Chaniad P; Phuwajaroanpong A; Konyanee A; Viriyavejakul P; Septama AW; Punsawad C
BMC Complement Med Ther; 2023 Sep; 23(1):332. PubMed ID: 37730604
[TBL] [Abstract][Full Text] [Related]
14. Oral Therapy Using a Combination of Nanotized Antimalarials and Immunomodulatory Molecules Reduces Inflammation and Prevents Parasite Induced Pathology in the Brain and Spleen of
Mukherjee S; Ray G; Saha B; Kar SK
Front Immunol; 2021; 12():819469. PubMed ID: 35095923
[TBL] [Abstract][Full Text] [Related]
15. Specific depletion of Ly6C(hi) inflammatory monocytes prevents immunopathology in experimental cerebral malaria.
Schumak B; Klocke K; Kuepper JM; Biswas A; Djie-Maletz A; Limmer A; van Rooijen N; Mack M; Hoerauf A; Dunay IR
PLoS One; 2015; 10(4):e0124080. PubMed ID: 25884830
[TBL] [Abstract][Full Text] [Related]
16. Disruption of Parasite hmgb2 Gene Attenuates Plasmodium berghei ANKA Pathogenicity.
Briquet S; Lawson-Hogban N; Boisson B; Soares MP; Péronet R; Smith L; Ménard R; Huerre M; Mécheri S; Vaquero C
Infect Immun; 2015 Jul; 83(7):2771-84. PubMed ID: 25916985
[TBL] [Abstract][Full Text] [Related]
17. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria.
Howland SW; Poh CM; Gun SY; Claser C; Malleret B; Shastri N; Ginhoux F; Grotenbreg GM; Rénia L
EMBO Mol Med; 2013 Jul; 5(7):984-99. PubMed ID: 23681698
[TBL] [Abstract][Full Text] [Related]
18. Human ApoE2 protects mice against
Liang R; Rao H; Pang Q; Xu R; Jiao Z; Lin L; Li L; Zhong L; Zhang Y; Guo Y; Xiao N; Liu S; Chen X-F; Su X-z; Li J
mBio; 2023 Oct; 14(6):e0234623. PubMed ID: 37874152
[TBL] [Abstract][Full Text] [Related]
19. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8
Wang Y; Shen Y; Liang J; Wang S; Huang Y; Zhu Q; Zhang X; Yu K; Tong G; Yang C; Li Y; Wang J; Zhao Y
J Neuroinflammation; 2024 May; 21(1):119. PubMed ID: 38715061
[TBL] [Abstract][Full Text] [Related]
20. Extracellular vesicles derived from plasmodium-infected red blood cells alleviate cerebral malaria in plasmodium berghei ANKA-infected C57BL/6J mice.
Lv Y; Wu S; Nie Q; Liu S; Xu W; Chen G; Du Y; Chen J
Int Immunopharmacol; 2024 May; 132():111982. PubMed ID: 38569430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
